Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorTurner, N. C.
dc.contributor.authorAlarcón, E.
dc.contributor.authorArmstrong, A. C.
dc.contributor.authorPhilco, M.
dc.contributor.authorLópez Chuken, Y. A.
dc.contributor.authorSablin, Marie-Paule
dc.contributor.authorAntunes de Melo Oliveira, Ana Mafalda
dc.date.accessioned2021-03-16T09:36:56Z
dc.date.available2021-03-16T09:36:56Z
dc.date.issued2019-05-01
dc.identifier.citationTurner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, et al. BEECH: A dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA. Ann Oncol. 2019 May 1;30(5):774–80.
dc.identifier.issn1569-8041
dc.identifier.urihttp://hdl.handle.net/11351/5759
dc.descriptionInhibidor de l'AKT; PIK3CA; Capivasertib
dc.description.sponsorshipThis study was supported by AstraZeneca (no grant number applies).
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.ispartofseriesAnnals of Oncology;30(5)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectEstrògens - Receptors
dc.subjectMetàstasi
dc.subjectMama - Càncer - Tractament
dc.subject.meshNeoplasm Metastasis
dc.subject.meshBreast Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshReceptors, Estrogen
dc.titleBEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1093/annonc/mdz086
dc.subject.decsmetástasis neoplásica
dc.subject.decsneoplasias de la mama
dc.subject.decs/farmacoterapia
dc.subject.decsreceptores de estrógenos
dc.relation.publishversionhttps://www.annalsofoncology.org/article/S0923-7534(19)31171-8/fulltext
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Turner NC] Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK. Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. [Alarcón E] Clinical Oncology Department, British American Hospital, Lima, Peru. [Armstrong AC] Department of Medical Oncology, Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. [Philco M] Peruvian Institute of Oncology Radiotherapy, Lima, Peru. [López Chuken YA] University Hospital, Monterrey, Mexico. [Sablin MP] Department of Drug Development and Innovation (D3i), Curie Institute, Paris, France. [Oliveira, M] Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid30860570
dc.identifier.wos000482490300013
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple